More recently, GLP-1 RA drugs have been approved for weight loss, cardiovascular disease, and chronic kidney disease
They can, however, be used to guide decision-making about the specific patient populations addressed in the trials
Considering the adherence of this patient, we chose dulaglutide, a once-weekly GLP-1 receptor agonist, instead of the once-daily GLP-1 receptor agonists
Defined as 12% body weight reduction per week without significant fatigue
Po pierwsze, eliminuje rekonstytucj: badacz pomija etap rozpuszczania proszku, doboru objtoci rozpuszczalnika i kontroli klarownoci
Weyand, [email protected] This article was submitted to Autoimmune and Autoinflammatory Disorders, a section of the journal Frontiers in Immunology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers